Direct tumor shots tested to revive immune attack on stubborn melanoma
NCT ID NCT04796194
Summary
This study tested a new approach for patients with advanced melanoma that had stopped responding to standard immunotherapy. Doctors injected an experimental drug called LTX-315 directly into accessible tumors, while also giving the immunotherapy drug pembrolizumab. The goal was to see if this combination could help the immune system recognize and fight the cancer again, and to check if it was safe for the 23 patients in the trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Akershus University Hospital
Lørenskog, Norway
-
Centre Hospitalier Regional Universitaire De Lille
Lille, France
-
Clínica Universidad de Navarra
Pamplona, Spain
-
Gustave Roussy Cancer Campus
Paris, France
-
Hospital Lyon Sud
Pierre-Bénite, France
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Levine Cancer Institute - Atrium Health
Charlotte, North Carolina, 28204, United States
-
MD Anderson Cancer Centre
Houston, Texas, 77030, United States
-
Oslo University Hospital--Radiumhospitalet
Oslo, Norway
-
University of Pittsburgh Medical Center (UPMC) Hilman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.